Abstract:Bone morphogenetic proteins (BMPs) are secreted cytokines that were initially discovered on the basis of their ability to induce bone. Several decades of research have now established that these proteins function in a large variety of physiopathological processes. There are about 15 BMP family members, which signal via three transmembrane type II receptors and four transmembrane type I receptors. Mechanistically, BMP binding leads to phosphorylation of the type I receptor by the type II receptor. This activated heteromeric complex triggers intracellular signaling that is initiated by phosphorylation of receptor‐regulated SMAD1, 5, and 8 (also termed R‐SMADs). Activated R‐SMADs form heteromeric complexes with SMAD4, which engage in specific transcriptional responses. There is convergence along the signaling pathway and, besides the canonical SMAD pathway, BMP‐receptor activation can also induce non‐SMAD signaling. Each step in the pathway is fine‐tuned by positive and negative regulation and crosstalk with other signaling pathways. For example, ligand bioavailability for the receptor can be regulated by ligand‐binding proteins that sequester the ligand from interacting with receptors. Accessory co‐receptors, also known as BMP type III receptors, lack intrinsic enzymatic activity but enhance BMP signaling by presenting ligands to receptors. In this review, we discuss the role of BMP receptor signaling and how corruption of this pathway contributes to cardiovascular and musculoskeletal diseases and cancer. We describe pharmacological tools to interrogate the function of BMP receptor signaling in specific biological processes and focus on how these agents can be used as drugs to inhibit or activate the function of the receptor, thereby normalizing dysregulated BMP signaling. © 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

Bone Morphogenetic Proteins In The Initiation And Progression Of Breast Cancer

Tgf-Beta and Bmp Signaling in Osteoblast, Skeletal Development, and Bone Formation, Homeostasis and Disease

BMP Signaling in the Development and Regeneration of Cranium Bones and Maintenance of Calvarial Stem Cells.

Roles of Bone Morphogenetic Proteins and Their Receptors in Mammalian Reproduction

When BMP Signalling Goes Wrong: the Intracellular and Molecular Mechanisms of BMP Signalling in Cancer

Biological Roles of Human Bone Morphogenetic Protein 9 in the Bone Microenvironment of Human Breast Cancer MDA-MB-231 Cells.

Bone Morphogenetic Protein Receptor Signal Transduction in Human Disease

Bone Morphogenetic Protein Signaling in Bone Homeostasis.

Bone Morphogenetic Proteins, Breast Cancer, and Bone Metastases: Striking the Right Balance

Bone Morphogenetic Proteins and Their Receptor Signaling in Prostate Cancer.

Bone morphogenetic protein signaling in bone homeostasis

The BMP Pathway and Its Inhibitors in the Skeleton

Secreted BMP Antagonists and Their Role in Cancer and Bone Metastases.

Bone Morphogenetic Protein (BMP) signaling in development and human diseases

Novel bone morphogenetic protein signaling through Smad2 and Smad3 to regulate cancer progression and development

Bone Morphogenetic Protein-Smad Pathway As Drug Targets for Osteoporosis and Cancer Therapy

BMP Signaling in Osteogenesis, Bone Remodeling and Repair

Tgf-Beta And Bmp Signaling In Osteoblast Differentiation And Bone Formation

Bone Morphogenetic Protein Receptors: Structure, Function and Targeting by Selective Small Molecule Kinase Inhibitors

Signal Transduction of Bone Morphogenetic Proteins in Osteoblast Differentiation.

The roles and regulatory mechanisms of TGF-β and BMP signaling in bone and cartilage development, homeostasis and disease